The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Open accessAbstract
BACKGROUND: Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end point from that trial as the primary end point. METHODS: We randomly assigned patients in a 1:1 ratio to receive intravenous anifrolumab (300 mg) or placebo every 4 weeks for 48 weeks. The primary end point of this trial was a response at week 52 defined with the use of the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA). A BICLA response requires reduction in any moderate-to-severe baseline disease activity and no worsening in any of nine organ systems in the BILAG index, no worsening on the Systemic Lupus Erythematosus Disease Activity Index, no increase of 0.3 points or more in the score on the Physician Global Assessment of disease activity (on a scale from 0 [no disease activity] to 3 [severe disease]), no discontinuation of the trial intervention, and no use of medications restricted by the protocol. Secondary end points included a BICLA response in patients with a high interferon gene signature at baseline; reductions in the glucocorticoid dose, in the severity of skin disease, and in counts of swollen and tender joints; and the annualized flare rate. RESULTS: A total of 362 patients received the randomized intervention: 180 received anifrolumab and 182 received placebo. The percentage of patients who had a BICLA response was 47.8% in the anifrolumab group and 31.5% in the placebo group (difference, 16.3 percentage points; 95% confidence interval, 6.3 to 26.3; P = 0.001). Among patients with a high interferon gene signature, the percentage with a response was 48.0% in the anifrolumab group and 30.7% in the placebo group; among patients with a low interferon gene signature, the percentage was 46.7% and 35.5%, respectively. Secondary end points with respect to the glucocorticoid dose and the severity of skin disease, but not counts of swollen and tender joints and the annualized flare rate, also showed a significant benefit with anifrolumab. Herpes zoster and bronchitis occurred in 7.2% and 12.2% of the patients, respectively, who received anifrolumab. There was one death from pneumonia in the anifrolumab group. CONCLUSIONS: Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a similar phase 3 trial involving patients with SLE that had a different primary end point. The frequency of herpes zoster was higher with anifrolumab than with placebo. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT02446899.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
(2007) · Systemic Lupus Erythematosus · doi:10.1016/b978-0-323-04434-9.50060-9 · Cited by 2,928
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationFurie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationCombined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Self-citationImmune Interferon in the Circulation of Patients with Autoimmune Disease
Hooks, J. J., Moutsopoulos, H. M., Geis, S. A., Stahl, N. I., Decker, J. L., & Notkins, A. L. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907053010102 · Cited by 921
Furie, R., Khamashta, M., Merrill, J. T., Werth, V. P., Kalunian, K., Brohawn, P., Illei, G. G., Drappa, J., Wang, L., Yoo, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39962 · Cited by 882
Self-citationPersonalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., Cepika, A.-M., Acs, P., Turner, J., Anguiano, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.008 · Cited by 731
Isenberg, D. A., Rahman, A., Allen, E., Farewell, V., Akil, M., Bruce, I. N., D'Cruz, D., Griffiths, B., Khamashta, M., Maddison, P., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/keh624 · Cited by 636
Self-citationBruce, I. N., O'Keeffe, A. G., Farewell, V., Hanly, J. G., Manzi, S., Su, L., Gladman, D. D., Bae, S.-C., Sanchez-Guerrero, J., Romero-Diaz, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205171 · Cited by 567
Self-citationFurie, R. A., Morand, E. F., Bruce, I. N., Manzi, S., Kalunian, K. C., Vital, E. M., Lawrence Ford, T., Gupta, R., Hiepe, F., Santiago, M., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30076-1 · Cited by 512
Self-citationAlbrecht, J., Taylor, L., Berlin, J. A., Dulay, S., Ang, G., Fakharzadeh, S., Kantor, J., Kim, E., Militello, G., McGinnis, K., et al. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23889.x · Cited by 510
Khamashta, M., Merrill, J. T., Werth, V. P., Furie, R., Kalunian, K., Illei, G. G., Drappa, J., Wang, L., & Greth, W. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208562 · Cited by 503
Self-citationNovel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationThe type I interferon system in systemic lupus erythematosus
Rönnblom, L., Eloranta, M., & Alm, G. V. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21571 · Cited by 341
Kalunian, K. C., Merrill, J. T., Maciuca, R., McBride, J. M., Townsend, M. J., Wei, X., Davis, J. C., & Kennedy, W. P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206090 · Cited by 340
Wallace, D. J., Kalunian, K., Petri, M. A., Strand, V., Houssiau, F. A., Pike, M., Kilgallen, B., Bongardt, S., Barry, A., Kelley, L., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202760 · Cited by 337
Some statistical methods for multiple endpoints in clinical trials
Zhang, J., Quan, H., Ng, J., & Stepanavage, M. E. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00129-8 · Cited by 170
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., Cepika, A.-M., Acs, P., Turner, J., Anguiano, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.057 · Cited by 170
Riggs, J. M., Hanna, R. N., Rajan, B., Zerrouki, K., Karnell, J. L., Sagar, D., Vainshtein, I., Farmer, E., Rosenthal, K., Morehouse, C., et al. (2018) · Lupus Science & Medicine · doi:10.1136/lupus-2018-000261 · Cited by 161
Numerical scoring for the BILAG-2004 index
Yee, C., Cresswell, L., Farewell, V. T., Rahman, A., Teh, L., Griffiths, B., Bruce, I. N., Ahmad, Y. A., Prabu, A., Akil, M., et al. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq026 · Cited by 147
Self-citationDefinition and treatment of lupus flares measured by the BILAG index
Gordon, C. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg382 · Cited by 141
Yao, Y., Higgs, B. W., Morehouse, C., Reyes, M. D. L., Trigona, W. L., Brohawn, P. Z., White, W. I., Zhang, J., White, B., Coyle, A. J., et al. (2008) · Human Genomics and Proteomics · doi:10.4061/2009/374312 · Cited by 140
Self-citationA recycling framework for the construction of Bonferroni‐based multiple tests
Burman, C., Sonesson, C., & Guilbaud, O. J. M. (2009) · Statistics in Medicine · doi:10.1002/sim.3513 · Cited by 140
Bengtsson, A. A., & Rönnblom, L. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.10.003 · Cited by 121
Yao, Y., Higgs, B. W., Richman, L. K., White, B., & Jallal, B. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2887 · Cited by 82
Cited by
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S.-C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224762 · Cited by 1,081
Self-citationUpdate οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 753
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Systemic Lupus Erythematosus: A Review
Siegel, C. H., & Sammaritano, L. R. (2024) · JAMA · doi:10.1001/jama.2024.2315 · Cited by 535
Metadata
- Authors
- Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., & Tummala, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 211-221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995521654
- Cited by
- 1,379
- References
- 26
- FWCI
- 87.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.